Ultragenyx Pharmaceutical Inc. (RARE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RARE Revenue Growth
Revenue Breakdown (FY 2025)
RARE's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
RARE Revenue Analysis (2014–2025)
As of May 6, 2026, Ultragenyx Pharmaceutical Inc. (RARE) generated trailing twelve-month (TTM) revenue of $672.7 million, reflecting exceptional growth of +25.5% year-over-year. The most recent quarter (Q4 2025) recorded $207.0 million in revenue, up 29.4% sequentially.
Looking at the longer-term picture, RARE's 5-year compound annual growth rate (CAGR) stands at +19.9%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $673.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows RARE's business is primarily driven by Product (55%), and Royalty (45%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BMRN (+9.9% YoY), SRPT (+47.1% YoY), and IONS (+47.5% YoY), RARE has underperformed the peer group in terms of revenue growth. Compare RARE vs BMRN →
RARE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RARECurrent | $673M | +25.5% | +19.9% | -79.5% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 SRPT | $1.9B | +47.1% | +37.9% | 11.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 ACAD | $958M | +12.7% | +23.1% | 24.1% | |
 FOLD | $528M | +21.3% | +23.7% | 4.7% |
RARE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $673.0M | +20.1% | $564.0M | 83.8% | $-535,000,000 | -79.5% |
| 2024 | $560.2M | +29.0% | $483.5M | 86.3% | $-535,973,000 | -95.7% |
| 2023 | $434.2M | +19.5% | $389.0M | 89.6% | $-569,208,000 | -131.1% |
| 2022 | $363.3M | +3.4% | $335.0M | 92.2% | $-648,919,000 | -178.6% |
| 2021 | $351.4M | +29.7% | $335.4M | 95.4% | $-381,737,000 | -108.6% |
| 2020 | $271.0M | +161.3% | $264.9M | 97.7% | $-330,116,000 | -121.8% |
| 2019 | $103.7M | +101.4% | $94.7M | 91.3% | $-424,173,000 | -409.0% |
| 2018 | $51.5M | +1871.5% | $50.3M | 97.8% | $-371,373,000 | -721.2% |
| 2017 | $2.6M | +1863.9% | $2.6M | 100.0% | $-328,942,000 | -12593.5% |
| 2016 | $133K | - | $-183,071,000 | -137647.4% | $-248,007,000 | -186471.4% |
See RARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RARE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RARE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRARE — Frequently Asked Questions
Quick answers to the most common questions about buying RARE stock.
Is RARE's revenue growth accelerating or slowing?
RARE revenue is accelerating at +25.5% year-over-year, exceeding the 5-year CAGR of +19.9%. TTM revenue reached $673M. Growth momentum has increased versus prior periods.
What is RARE's long-term revenue growth rate?
Ultragenyx Pharmaceutical Inc.'s 5-year revenue CAGR of +19.9% reflects the sustained expansion pattern. Current YoY growth of +25.5% is above this long-term average.
How is RARE's revenue distributed by segment?
RARE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.